

〔一般論文〕

## 推奨後発医薬品選定による使用推進の取り組み

### Approach for Promoting the Use of Generic Drugs through Selection of Recommended Drugs

金田 孝子\*, 鏑木 芳夫, 寺島 裕子, 井上 道生  
中井 達宏, 土屋 大輔, 秋山 昌之  
TAKAKO KANEDA\*, YOSHIO KABURAKI, YUKO TERASHIMA, MICHIO INOUE,  
TATSUHIRO NAKAI, DAISUKE TSUCHIYA, MASAYUKI AKIYAMA

ファーマライズ医薬情報研究所 DI 室

[ Received August 29, 2012  
Accepted March 8, 2013 ]

**Summary:** New generic drugs are put on the market twice a year in Japan. On these occasions, more than twenty companies release new generic drugs for popular applications. In our company, pharmacists who work for health insurance pharmacies have to select from such newly released drugs in addition to their busy routine work schedule. Switching from prescribed drugs to equivalent generic drugs by pharmacists was admitted in 2006. Since that time, our DI Office has established criteria for selection, in collaboration with manufacturers of generic drugs, for the purpose of promoting the use of generic drugs. We have selected recommended generic drugs based on those criteria. We have also formulated a list of recommended generic drugs to enable comparison between selection items, and provided the list to drugstores as supporting materials for selection. We also asked drugstores to submit generic drug reports whenever they received complaints from patients following use, they had problems related to delivery, etc., so that the relevant information is shared throughout the company. Seventy to eighty percent of Amlodipine generic tablets that were actually prescribed were took up by items on the list of recommended generic drugs, proving the validity and effects of our selection criteria.

**Key words:** selection criteria for generic drugs, list of recommended generic drugs, generic drug reports, promoting the use of generic drugs

**要旨:** 後発医薬品（以下：後発品）の発売は、年2回あり、繁用医薬品では20社以上が同時発売する。当社の保険薬局の薬剤師は、多忙な日常業務の中で採用の選定をしなければならない。当社DI室では、処方せんが後発品に変更可能になった2006年より、後発品使用促進を目的として、後発品メーカーと医薬品について選定基準を設定し、それに基づいて推奨後発品を選定してきた。また、選択項目を比較できる「推奨後発品リスト」を作成し、選択の資料として店舗に提供し支援してきた。更に、店舗からは、使用後の患者からの苦情や供給面などについて問題があった際に、「後発品報告書」を提出してもらい、社内での情報の共有化を図った。アムロジピン錠の後発品の使用量は、70～80%推奨後発品に集約されており、選定基準の妥当性とその効果が確認できた。

**キーワード:** 後発品選定基準, 推奨後発品リスト, 後発品報告書, 後発品使用促進

\* 〒164-0011 東京都中野区中央 1-38-1  
TEL : 03-3362-7130 (代) FAX : 03-3362-7190  
E-mail : t-kaneda@pharmarise.co.jp